Video

Rahul Khurana: Intravitreal Injections a Difficult Treatment Choice but Often Better Than Blindness

Author(s):

The discussion of intravitreal injections may not be an easy one for doctors to have with their patients, but when the full treatment picture is explained it can show how the benefits outweigh other potential issues.

The discussion of intravitreal injections may not be an easy one for doctors to have with their patients, but when the full treatment picture is explained it can show how the benefits outweigh other potential issues.

Rahul N. Khurana, MD, from Northern California Retina Vitreous Associates, said that while diagnosing conditions like central retinal vein occlosion can be done by most eyecare professionals the treatment, especially when it comes to injections, should only be done by specialists with experience in the field. Khurana also said that communication from diagnosis through treatment can often make a big difference in how receptive a patient is to the process as a whole.

Related Videos
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
© 2024 MJH Life Sciences

All rights reserved.